HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease. Sean Korbitz had his first bout with cancer — a brain tumor discovered after six ...
WELIREG Approved for Adult Patients With VHL Disease Who Require Therapy for Associated Renal Cell Carcinoma, Central Nervous System Hemangioblastomas, or Pancreatic Neuroendocrine Tumors, Not ...
Researchers have mapped all the possible outcomes of changes to a tumor-suppressing gene called VHL, the first step in a huge research endeavor to unpick the outcomes of tens of thousands of genetic ...
HOUSTON ― Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible ...
Symptomatic brain metastases from renal cell carcinoma during treatment with sunitinib or sorafenib. Background: Germline mutations in the VHL gene cause VHL syndrome. Functional loss of the VHL gene ...
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted ...
Von Hippel-Lindau disease (VHL), also called VHL syndrome, is a rare genetic disorder that causes tumors and cysts to form throughout your body. VHL disease can be found all over the world across all ...
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results